



# Cross-Canada Rounds

Danielle Adam, PGY5  
Pediatric Respiriology Fellow  
December 20th, 2018



# Case



# Case

- ▶ 14yo male: referred for poorly controlled asthma and persistent Xray changes
- ▶ Diagnosed at age 3 (recurrent cough and wheezing)
- ▶ Previous treatment: Flovent and Symbicort PRN
- ▶ Present treatment (for the last year): Zenhale 100mcg 2 puffs BID, Singulair 5mg once daily, and Nasonex, no Ventolin use last year
  - ▶ Ventolin has helped in the past

# Case

- ▶ Present symptoms: chest tightness and SOB with exercise (5min of running)
- ▶ Exercises 4 times a week
- ▶ Chronic dry cough every night
- ▶ Only sick once this winter with a cold
- ▶ Previous illnesses: LUL pneumonia – treated with abx with incomplete resolution (persistent x-ray changes). Repeated abx and prednisone

# Case: Past Medical History

- ▶ Adopted as a baby, no neonatal respiratory distress
- ▶ No hospitalizations, surgeries
- ▶ Several childhood visit to the ER for asthma and received steroids multiple times (last oral steroids for asthma was 5 years ago)
- ▶ Suspected allergies to cats, dogs, dust
- ▶ Family history: limited known about biological family except for history of CF

# Case: Review of Systems

- ▶ Chronic nasal congestion, no polyps
- ▶ No history of choking or coughing with eating
- ▶ Normal bowel movements
- ▶ No eczema history
- ▶ No snoring
- ▶ Growing well
- ▶ Multiple ear infections in early childhood but otherwise no history to suggest immunodeficiency

# Chest X-Ray




Any additional investigations you want to do?

SPIROMETRY		Ref	Pre Meas	Pre % Ref	Post Meas	Post % Ref	Post % Chg
FVC	Liters	4.13	4.88	118	4.76	115	-3
FEV1	Liters	3.81	3.81	100	3.69	97	-3
FEV1/FVC	%	86	78	91	78	90	-1
FEF25-75%	L/sec	4.19	3.32	79	3.26	78	-2
FEF50%	L/sec	4.73	4.56	96	4.45	94	-2
FEF75%	L/sec	2.63	1.57	60	1.38	52	-12
PEF	L/sec	7.91	8.41	106	8.88	112	6
FIVC	Liters		3.70		2.63		-29
PIF	L/sec		5.11		5.56		9
MVV	L/min						

LUNG VOLUMES (PLETHYSMOGRAPHY)		Ref	Pre Meas	Pre % Ref
VC		4.13	5.19	126
TLC PI		5.27	6.67	127
RV	Liters	1.08	1.48	137
RV/TLC	%	20	22	108
FRC PL	Liters	2.49	3.56	143
IC	Liters		3.11	
ERV	Liters		2.10	


DIFFUSION CAPACITY		Ref	Pre Meas	Pre % Ref
DLCO	mL/mmHg/min	28.6	28.5	100
DL Adj	mL/mmHg/min	28.6	28.5	100
VA	Liters	5.27	5.70	108
DLCO adj for VA		28.6	27.6	97
IVC	Liters		4.78	

AIRWAYS RESISTANCE		Ref	Pre Meas	Pre % Ref
Raw	cmH2O/L/sec	2.28		
Gaw	L/sec/cmH2O	0.119		
sRaw	cmH2O/L/s/L	5.97		
sGaw	L/s/cmH2O/L	0.168		
Vtg (Raw)	Liters			



#### COMMENTS:

The patient provided good effort, however, was unable to meet end of test criteria for flow volume loops- ATS criteria were not met. Lung volumes and DLCO testing met ATS criteria. 4 puffs of bronchodilator - Salbutamol, were administered via space chamber.






# Case: Next steps

- ▶ CT
- ▶ Allergy test: Positive for horse, trees, indoor and outdoor molds, house dust mites and cat
- ▶ CBC: normal

CT




# Follow-up

- ▶ His Singulair was optimized to 10mg once daily and he as given a Ventolin discus to take with exercise. He was told to remain on the Zenhale
- ▶ He returned to clinic 4-6 weeks later and is very happy with the improvement.
- ▶ He is now completely asymptomatic


## SPIROMETRY

		Ref	Pre Meas	Pre % Ref	Post Meas	Post % Ref	Post % Chg
FVC	Liters	4.27	4.99	117	4.93	115	-1
FEV1	Liters	3.94	3.78	96	3.89	99	3
FEV1/FVC	%	86	76	88	79	92	4
FEF25-75%	L/sec	4.32	3.10	72	3.51	81	13
FEF50%	L/sec	4.89	3.96	81	4.33	89	9
FEF75%	L/sec	2.74	1.42	52	1.63	59	14
PEF	L/sec	8.14	8.55	105	8.42	103	-2
FET100%	Sec		4.86		6.49		34
FIVC	Liters		4.45		4.58		3
PIF	L/sec		8.39		8.42		0
MVV	L/min						



### COMMENTS:

Last used Zenhale approximately 16 hours prior to testing, has not used Ventolin over past month. 4 puffs of bronchodilator - Salbutamol, were administered via space chamber. The patient provided adequate effort, flow volume loop testing met ATS criteria.



# Case – more details

- ▶ Sweat chloride: 59 (repeat 58)
- ▶ IgE: 8981
- ▶ Bronch: lipid laden macrophages, no bacterial growth, scant secretions

# Outline

- ▶ To review the criteria and suggested workup for difficult to treat asthma.
- ▶ To review normal sweat chloride levels, and what it could mean to have an indeterminate sweat chloride level
- ▶ To outline the possible relationship of elevated sweat chloride levels and difficult to treat asthma



# Difficult to Treat Asthma

DEFINITION

WORK-UP

SWEAT CHLORIDE LINK?

# Definition

“Recognition and management of severe asthma:  
A Canadian Thoracic Society position statement”

## Severe asthma

Asthma which requires treatment with high-dose ICS as outlined in Table 1 (adults and children) and a second controller for the previous year, or systemic corticosteroids for 50% of the previous year to prevent it from becoming “uncontrolled”, or which remains “uncontrolled” despite this therapy is defined as severe asthma.

**Uncontrolled asthma** is defined as at least one of the following:

- 1) Poor symptom control: *as per* Canadian Thoracic Society asthma control criteria\* or other standardized questionnaires: Asthma Control Questionnaire (ACQ) consistently  $> 1.5$ , Asthma Controlled Test (ACT)  $< 20$ , or child Asthma Controlled Test (cACT)  $< 20$ .
- 2) Frequent severe exacerbations: two or more courses of systemic corticosteroids ( $\geq 3$  days each) in the previous year.
- 3) Serious exacerbations: at least one hospitalization, intensive care unit (ICU) stay or mechanical ventilation in the previous year.
- 4) Airflow limitation: after appropriate bronchodilator withhold forced expiratory volume in one second ( $FEV_1$ )  $< 80\%$  of personal best (or  $<$  the lower limit of normal (LLN), in the face of reduced  $FEV_1$ /forced vital capacity (FVC) defined as less than the LLN).

\*Not meeting the criteria described in Table 2.<sup>5</sup>



# CTS Position Statement

- ▶ “A diagnosis of asthma using **objective measures**, the assessment of **domestic and work environment** along with the **verification of adherence to medication and co-morbidities** is key”
- ▶ Non-adherence to treatment = major challenge
- ▶ Another issue: incorrect use of inhalers
- ▶ Consider co-morbidities during initial assessment esp if:
  - ▶ Lack of response to ICS with another controller
  - ▶ Usual management of the most frequent reasons for poor control

# A Practical Approach to Severe Asthma in Children

Emily E. Barsky<sup>1,2</sup>, Lauren M. Giancola<sup>1</sup>, Sachin N. Baxi<sup>2,3</sup>, and Jonathan M. Gaffin<sup>1,2</sup>

<sup>1</sup>Division of Respiratory Diseases and <sup>3</sup>Division of Allergy and Immunology, Department of Medicine, Boston Children's Hospital, Boston, Massachusetts; and <sup>2</sup>Harvard Medical School, Boston, Massachusetts

- ▶ Step 1: Diagnosis Confirmation
- ▶ Step 2: Evaluation and Optimization of Difficult to Treat Asthma
- ▶ Step 3: Assessment and Management of Severe Asthma Refractory to Traditional Therapy
- ▶ Step 4: Efficacy Assessment

# A Practical Approach to Severe Asthma in Children

Emily E. Barsky<sup>1,2</sup>, Lauren M. Giancola<sup>1</sup>, Sachin N. Baxi<sup>2,3</sup>, and Jonathan M. Gaffin<sup>1,2</sup>

<sup>1</sup>Division of Respiratory Diseases and <sup>3</sup>Division of Allergy and Immunology, Department of Medicine, Boston Children's Hospital, Boston, Massachusetts; and <sup>2</sup>Harvard Medical School, Boston, Massachusetts

## Step 1: Diagnosis Confirmation

- ▶ 30% of referrals for severe asthma = misdiagnosed
- ▶ History, physical and spirometry
- ▶ Atypical presentations
- ▶ Consider: lung volumes, sweat test, bronchoscopy, CT

# A Practical Approach to Severe Asthma in Children

Emily E. Barsky<sup>1,2</sup>, Lauren M. Giancola<sup>1</sup>, Sachin N. Baxi<sup>2,3</sup>, and Jonathan M. Gaffin<sup>1,2</sup>

<sup>1</sup>Division of Respiratory Diseases and <sup>3</sup>Division of Allergy and Immunology, Department of Medicine, Boston Children's Hospital, Boston, Massachusetts; and <sup>2</sup>Harvard Medical School, Boston, Massachusetts

## Step 2/3: Evaluation and Optimization of Difficult to Treat Asthma & Asthma refractory to traditional therapy

- ▶ Adherence, technique and optimizing delivery
- ▶ Use of technology
- ▶ Environment
- ▶ Management (refractory disease)
  - ▶ Steroids (oral)
  - ▶ Anticholinergics
  - ▶ Biologics

# A Practical Approach to Severe Asthma in Children

Emily E. Barsky<sup>1,2</sup>, Lauren M. Giancola<sup>1</sup>, Sachin N. Baxi<sup>2,3</sup>, and Jonathan M. Gaffin<sup>1,2</sup>

<sup>1</sup>Division of Respiratory Diseases and <sup>3</sup>Division of Allergy and Immunology, Department of Medicine, Boston Children's Hospital, Boston, Massachusetts; and <sup>2</sup>Harvard Medical School, Boston, Massachusetts

## Emerging therapeutic considerations:

- ▶ Increased inhaled steroids during exacerbations
- ▶ Theophylline
- ▶ Additional biologics
- ▶ Antimicrobial drugs
- ▶ Immunosuppressants
- ▶ Allergen immunotherapy
- ▶ Surgical Intervention

# Sweat Chloride

THE INDETERMINATE LEVEL  
IS THERE A LINK TO DTT  
ASTHMA?

## **FALSE-POSITIVE**

---

Adrenal insufficiency

Eczema

Ectodermal dysplasia

Nephrogenic diabetes insipidus

Hypothyroidism

Fucosidosis

Mucopolysaccharidosis

Dehydration

Malnutrition

Poor technique/inadequate sweat collection

Type I glycogen storage disease

Panhypopituitarism

Pseudohypoaldosteronism

Hypoparathyroidism

Prostaglandin E<sub>1</sub> administration

---

## **FALSE-NEGATIVE**

---

Edema

Poor technique/inadequate sweat collection

---

# Sweat Chloride Ranges

## Diagnosis

- $>60\text{mmol/L}$

+ NBS  
Clinical history  
+ Family history

## Intermediate

- 30-  
59mmol/L

Consider extended  
CFTR genetic analysis

## Unlikely

- $<30\text{mmol/L}$

CF is unlikely



# Diagnostic Definitions

## CF

- clinical presentation and CFTR dysfunction

## CFMS/CFSPID

- Infants with positive NBS AND EITHER:
  - Sweat chloride  $<30$  + 2 CFTR mutations
  - Indeterminate sweat chloride and 1 or 0 mutations

## CFTR-related

- Symptoms that related to CFTR dysfunction but not full CF criteria

# Indeterminate Sweat – Thoughts?

- ▶ Sweat chloride = good discriminating test but **normal adults can have values as high as 50 and 60**
- ▶ Sweat chloride values increase with age → higher with normal adolescents and adults
- ▶ Does lowering the borderline cut-off for sweat chloride impact the diagnostic process?

1. Hodson et al. (1983). Sweat test used to diagnose CF in adults, *BMJ*

2. Leigh, M (2004). Diagnosis of CF despite normal or borderline sweat chloride. *Paeds Resp Reviews*

3. Cirilli et al (2018) May the new suggested lower borderline limit of sweat chloride impact the diagnostic process for CF?" *The journal of Pediatrics*

## Borderline sweat test: Utility and limits of genetic analysis for the diagnosis of cystic fibrosis<sup>☆</sup>

Manuela Seia <sup>a,\*</sup>, Lucy Costantino <sup>a</sup>, Valentina Paracchini <sup>a</sup>, Luigi Porcaro <sup>a</sup>, Patrizia Capasso <sup>a</sup>,  
Domenico Coviello <sup>a</sup>, Carlo Corbetta <sup>b</sup>, Erminio Torresani <sup>c</sup>, Domenico Magazzù <sup>d</sup>,  
Vincenza Consalvo <sup>a</sup>, Alice Monti <sup>e</sup>, Diana Costantini <sup>e</sup>, Carla Colombo <sup>e</sup>

- ▶ CFTR mutation analysis and borderline sweat chloride concentration
- ▶ The mean value in the DNA negative subjects was significantly lower than in those with at least one CFTR mutation
- ▶ Subjects with a sweat value <39 mEq/l are **unlikely to carry variant/mutation in the CFTR gene** and genetic analysis may be performed only in subjects with chloride values >39 mEq/l.

# Elevated Sweat Chloride Levels and Asthma

IS THERE AN ASSOCIATION?

# Sweat Chloride Levels and Asthma

- ▶ Research suggests there could be a link between higher sweat chloride levels in asthmatics compared to healthy controls
  - ▶ Generally, these values are still under 40mmol/L
- ▶ Others have not found a difference between healthy controls and those with asthma
- ▶ A history of several asthma exacerbations and recurrent pneumonia should prompt consideration of a sweat test

Awasthi et al. Higher sweat chloride levels in patients with asthma: a case-control study. Indian J Pediatr. 2014.

Gharib et al. Sweat chloride concentration; a comparative study in children with bronchial asthma and with cystic fibrosis. Am J Dis Child. 1965;109:66–8

Mandal et Kabra, Sweat Chloride Levels in Asthma Indian J Pediatr (February 2015) 82(2):103–104

# Sweat Chloride Levels and Asthma

- ▶ ?related to Ventolin use (selective beta-2 agonist)
  - ▶ Hypokalemia → increased chloride levels
- ▶ Asthmatics are more likely to receive steroids
  - ▶ associated with sodium retention which directly correlates with increased level of chloride in sweat.

## Severe asthma and cystic fibrosis: Overlapping phenotypes?

Giovanna Riolo<sup>a</sup>, Kelly M. Rodrigues<sup>b,c</sup>, Cathy E. Dai<sup>b,c</sup>, Andrew G. Day<sup>d</sup>, and M. Diane Lougheed<sup>b,c,d</sup>

<sup>a</sup>Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada; <sup>b</sup>Asthma Research Unit, Kingston Health Sciences Centre, Kingston, Ontario, Canada; <sup>c</sup>Department of Medicine, Queen's University, Kingston, Ontario, Canada; <sup>d</sup>Clinical Research Centre, Kingston General Hospital Research Institute, Kingston, Ontario, Canada

- ▶ ~10% of individuals with asthma have severe disease
- ▶ Heterozygosity for CF has been associated with increased airway reactivity → airflow obstruction
- ▶ Heterozygosity for CFTR gene mutations → ?predisposition to the development of asthma
- ▶ Possible association between CFTR mutations and asthma severity

## Severe asthma and cystic fibrosis: Overlapping phenotypes?

Giovanna Riolo<sup>a</sup>, Kelly M. Rodrigues<sup>b,c</sup>, Cathy E. Dai<sup>b,c</sup>, Andrew G. Day<sup>d</sup>, and M. Diane Lougheed<sup>b,c,d</sup>

<sup>a</sup>Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada; <sup>b</sup>Asthma Research Unit, Kingston Health Sciences Centre, Kingston, Ontario, Canada; <sup>c</sup>Department of Medicine, Queen's University, Kingston, Ontario, Canada; <sup>d</sup>Clinical Research Centre, Kingston General Hospital Research Institute, Kingston, Ontario, Canada

- ▶ Some studies suggest an association between being heterozygous for a CFTR gene mutation and forms of pulmonary diseases, including asthma and ABPA.
  - ▶ Others have suggested CFTR mutations may be protective against bronchial asthma (or no relationship at all)
- ▶ ATS/ERS and CTS recommend screening for CF in cases of severe asthma



# Risk of asthma in heterozygous carriers for cystic fibrosis: A meta-analysis



Anne Orholm Nielsen<sup>a</sup>, Sadaf Qayum<sup>a</sup>, Pierre Nouridine Bouchelouche<sup>a</sup>, Lars Christian Laursen<sup>b</sup>,  
Ronald Dahl<sup>c</sup>, Morten Dahl<sup>a,\*</sup>

- ▶ The risk of asthma was significantly higher in people heterozygous for CF than in non-carriers
- ▶ Is asthma a CFTR-related disorder?
  - ▶ reduction of CFTR function vs interaction

# Non-allergic asthma as a CFTR-related disorder☆

Angela Schulz, Burkhard Tümmler \*

- ▶ CF-like symptoms with inconclusive CFTR genotype and sweat chloride concentrations → non-allergic asthma
- ▶ Childhood history of obstructive lung disease and recurrent airway infections.
- ▶ The sweat chloride: **normal to borderline range**
- ▶ A CFTR-related disorder may manifest in childhood with obstructive lung disease that is classified as an intrinsic or non-allergic asthma

# Case: Additional Results

- ▶ common CF genetic mutations - **pending**
- ▶ cough swab: negative
- ▶ fecal elastase: **indeterminate range**
- ▶ liver enzymes, glucose and iron studies - normal
- ▶ repeat immunoglobulins and vaccine titres - normal
- ▶ nasal brush biopsy – **pending**
- ▶ Vitamin A level: **low**

# Take Home Points

- ▶ If the "asthma" doesn't fit like asthma, trust your gut
- ▶ Consider the broad differential for asthma and if suspected, include additional investigations such as lung volumes, sweat test, bronch with BAL, HRCT, PCD
- ▶ Children with asthma have been found to have higher sweat chloride levels than their "non-asthma" peers, although this is still usually in the normal range
- ▶ Sweat chloride levels tend to increase with age, so normal adolescents and adults may have a sweat chloride over 50-60

# References

- ▶ FitzGerald et al. Recognition and management of severe asthma: A Canadian Thoracic Society position statement (2017)
- ▶ CF Foundation
- ▶ Barsky et al. Practical approach to severe asthma in children (2017). Focused Review
- ▶ Hodson et al. (1983). Sweat test used to diagnose CF in adults, BMJ
- ▶ Leigh, M (2004). Diagnosis of CF despite normal or borderline sweat chloride. Paeds Resp Reviews
- ▶ Ciriilli et al (2018) May the new suggested lower borderline limit of sweat chloride impact the diagnostic process for CF?" The journal of Pediatrics
- ▶ Seia et al. Borderline sweat test: Utilities and limits of genetic analyses to diagnose CF. Clinical Biochemistry 42 (2009) 611–616
- ▶ Awasthi et al. Higher sweat chloride levels in patients with asthma: a case-control study. Indian J Pediatr. 2014.
- ▶ Mandal et Kabra, Sweat Chloride Levels in Asthma Indian J Pediatr (February 2015) 82(2):103–104

# References

- ▶ Gharib et al. Sweat chloride concentration; a comparative study in children with bronchial asthma and with cystic fibrosis. *Am J Dis Child*. 1965;109:66–8
- ▶ Riolo. Severe asthma and CF: Overlapping phenotypes
- ▶ Nielson: Risk of asthma in Heterozygous carriers for CF. *Journal of Cystic Fibrosis* 15 (2016) 563–567
- ▶ Corvol et al. Are CF carriers predisposed to asthma? *Journal of Cystic Fibrosis* 15 (2016) 555–556
- ▶ Schulz et al. Non-allergic asthma as a CFTR related disorder
- ▶ Noone et al. 'CFTR-opathies': disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations
- ▶ Miller PW et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. *Am J Hum Genet* 1996, 59:45-51.

Questions?

